Latest Insider Transactions at Atreca, Inc. (BCEL)
This section provides a real-time view of insider transactions for Atreca, Inc. (BCEL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Atreca, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Atreca, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 11
2024
|
John A Orwin PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$0
$0.01 P/Share
|
|
Apr 01
2024
|
Tito Serafini |
SELL
Open market or private sale
|
Direct |
20,788
-32.27%
|
$0
$0.07 P/Share
|
|
Oct 19
2023
|
Baker Bros. Advisors LP |
SELL
Open market or private sale
|
Indirect |
274,739
-7.59%
|
$0
$0.4 P/Share
|
|
Sep 01
2023
|
Tito Serafini |
SELL
Open market or private sale
|
Direct |
8,393
-11.53%
|
$0
$0.37 P/Share
|
|
Sep 01
2023
|
John A Orwin PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
22,951
-22.84%
|
$0
$0.37 P/Share
|
|
Sep 01
2023
|
Phillips Courtney GENERAL COUNSEL & SECRETARY |
SELL
Open market or private sale
|
Direct |
7,061
-12.28%
|
$0
$0.37 P/Share
|
|
Aug 02
2023
|
Herb Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,487
-7.01%
|
$0
$0.95 P/Share
|
|
Aug 02
2023
|
Tito Serafini |
SELL
Open market or private sale
|
Direct |
5,487
-7.01%
|
$0
$0.95 P/Share
|
|
Aug 02
2023
|
Phillips Courtney GENERAL COUNSEL & SECRETARY |
SELL
Open market or private sale
|
Direct |
4,076
-6.62%
|
$0
$0.95 P/Share
|
|
Aug 02
2023
|
Stephen E Gould Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,076
-12.54%
|
$0
$0.95 P/Share
|
|
Feb 09
2023
|
Phillips Courtney GENERAL COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+34.55%
|
-
|
|
Feb 09
2023
|
Tito Serafini |
SELL
Grant, award, or other acquisition
|
Direct |
43,750
-35.84%
|
-
|
|
Feb 09
2023
|
Herb Cross Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+35.84%
|
-
|
|
Feb 09
2023
|
Stephen E Gould Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+50.0%
|
-
|
|
Sep 02
2022
|
Tito Serafini |
SELL
Open market or private sale
|
Direct |
7,646
-18.12%
|
$7,646
$1.78 P/Share
|
|
Sep 02
2022
|
John A Orwin PRESIDENT & CEO |
SELL
Open market or private sale
|
Direct |
20,908
-17.22%
|
$20,908
$1.78 P/Share
|
|
Sep 02
2022
|
Herb Cross Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,646
-18.12%
|
$7,646
$1.78 P/Share
|
|
Sep 02
2022
|
Phillips Courtney GENERAL COUNSEL & SECRETARY |
SELL
Open market or private sale
|
Direct |
6,432
-18.12%
|
$6,432
$1.78 P/Share
|
|
Jun 28
2022
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
15,000
-6.15%
|
$30,000
$2.02 P/Share
|
|
Mar 04
2022
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
30,000
-10.95%
|
$150,000
$5.0 P/Share
|
|
Sep 27
2021
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
30,000
-9.87%
|
$180,000
$6.58 P/Share
|
|
Sep 20
2021
|
Tito Serafini |
BUY
Bona fide gift
|
Indirect |
50,000
+50.0%
|
-
|
|
Sep 20
2021
|
Tito Serafini |
SELL
Bona fide gift
|
Indirect |
50,000
-14.13%
|
-
|
|
Sep 09
2021
|
Tito Serafini |
BUY
Grant, award, or other acquisition
|
Direct |
42,200
+50.0%
|
-
|
|
Sep 09
2021
|
Phillips Courtney GENERAL COUNSEL & SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
35,500
+50.0%
|
-
|
|
Sep 09
2021
|
Herb Cross Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,200
+50.0%
|
-
|
|
Sep 09
2021
|
John A Orwin PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,400
+48.73%
|
-
|
|
Mar 17
2021
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$80,000
$16.73 P/Share
|
|
Mar 17
2021
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$20,000
$4.86 P/Share
|
|
Mar 15
2021
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.34%
|
$80,000
$16.89 P/Share
|
|
Mar 11
2021
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
10,000
-1.38%
|
$180,000
$18.53 P/Share
|
|
Feb 17
2021
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$90,000
$18.95 P/Share
|
|
Feb 17
2021
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$25,000
$5.16 P/Share
|
|
Feb 16
2021
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.32%
|
$95,000
$19.07 P/Share
|
|
Feb 11
2021
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
10,000
-2.67%
|
$180,000
$18.93 P/Share
|
|
Jan 19
2021
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$75,000
$15.21 P/Share
|
|
Jan 19
2021
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$25,000
$5.16 P/Share
|
|
Jan 14
2021
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
2,259
-0.59%
|
$33,885
$15.06 P/Share
|
|
Jan 13
2021
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
2,741
-0.71%
|
$41,115
$15.05 P/Share
|
|
Jan 11
2021
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
10,000
-2.61%
|
$150,000
$15.02 P/Share
|
|
Dec 17
2020
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$80,000
$16.61 P/Share
|
|
Dec 17
2020
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$20,000
$4.56 P/Share
|
|
Dec 14
2020
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.29%
|
$80,000
$16.67 P/Share
|
|
Dec 11
2020
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
10,000
-2.54%
|
$150,000
$15.87 P/Share
|
|
Nov 27
2020
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,175
-100.0%
|
$47,625
$15.34 P/Share
|
|
Nov 27
2020
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,175
+50.0%
|
$12,700
$4.56 P/Share
|
|
Nov 17
2020
|
Norman Michael Greenberg Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,825
-100.0%
|
$27,375
$15.04 P/Share
|
|
Nov 17
2020
|
Norman Michael Greenberg Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,825
+50.0%
|
$7,300
$4.56 P/Share
|
|
Nov 16
2020
|
Tito Serafini |
SELL
Open market or private sale
|
Indirect |
8,847
-2.2%
|
$132,705
$15.12 P/Share
|
|
Nov 16
2020
|
William Hewitt Robinson Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.27%
|
$75,000
$15.0 P/Share
|